Sermorelin vs Ipamorelin
GHRH Analog · Growth Hormone Secretagogue
Here is how these two compounds compare, based on published research, not marketing claims.
Sermorelin
The closest peptide to the body's natural growth hormone release signal; historically FDA-approved as Geref, discontinued for commercial reasons in 2008.
Ipamorelin
The most selective GH secretagogue documented; triggers GH release without raising cortisol, prolactin, or appetite.
Sermorelin
328 studies
20 human trials
Not FDA-Approved
Ipamorelin
48 studies
3 human trials
Not FDA-Approved
What it does
Sermorelin
Copies the working portion of the body's natural growth hormone signal directly, with no modifications added: just the first 29 amino acids of GHRH out of 44 in the full molecule. The original peptide in this class, and still the closest thing to what the brain actually produces. Half-life is short by design, on the order of 10 to 15 minutes, the same as native GHRH.
Ipamorelin
Releases growth hormone without the cortisol or prolactin spike that older ghrelin agonists produced. The most receptor-selective compound in the GH secretagogue class for GHS-R1a, the ghrelin receptor itself. Comparable growth hormone elevation to GHRP-2 or GHRP-6 in head-to-head studies, without the hormonal collateral that made those compounds harder to study.
How it works
Sermorelin
A lab-made copy of the first 29 amino acids of the body's natural growth hormone signal. It matches what the body already produces, which is why people call it the 'closest to natural' option.
Ipamorelin
Ipamorelin acts on a single receptor on the pituitary gland (the ghrelin receptor, GHS-R1a) and triggers growth hormone release without touching the cortisol axis, the prolactin axis, or the appetite signal that older compounds in this class also activated. Other GH secretagogues like GHRP-6 and hexarelin raise cortisol alongside GH, raise prolactin, and sharpen hunger. Ipamorelin does not.
How often
Sermorelin
In studies and historical clinical use as Geref, sermorelin was given as a daily subcutaneous injection, typically in the evening, which clinical literature describes as aligned with the body's natural overnight growth hormone pulse. The active window is brief, roughly ten minutes.
Ipamorelin
In published human pharmacokinetic studies (Johansen 1999), ipamorelin was given as a subcutaneous injection with dose-dependent GH response measured over hours. The Beck 2014 Phase II post-surgical trial used repeated dosing over days. Clinical protocols typically use daily subcutaneous injection, though this frequency derives from clinical practice rather than from controlled dose-optimization trials.
How strong
Sermorelin
Mild. A modest increase over the body's natural growth hormone release, not an override.
Ipamorelin
Moderate GH elevation with the cleanest hormonal profile in the secretagogue class. The GH pulse follows the body's natural pulsatile pattern rather than producing sustained elevation. The selectivity advantage is the pharmacological identity of the molecule.
Main tradeoff
Sermorelin
Daily injections. Subtler effects. Some people plateau after several months.
Ipamorelin
The selectivity that makes ipamorelin distinctive is well documented, but clinical outcome data beyond the single Phase II post-surgical GI trial (Beck 2014) is absent. One of the most widely used peptides in clinical practice has almost no published outcomes data for the endpoints practitioners actually prescribe it for. The CJC-1295 plus ipamorelin combination has never been tested in a controlled comparison study despite being the most common clinical protocol.
Best for
Sermorelin
- Beginners to peptides
- People who want the most 'natural' approach
- Anyone prioritizing a gentle, long-term effect over peak results
Ipamorelin
- Research interest in selective GH secretagogues with minimal off-target hormonal effects
- Research comparing GH secretagogue selectivity profiles across the class
- Research contexts where the CJC-1295 plus ipamorelin pairing is the protocol under study
How to choose
A good fit for Sermorelin
- Research on GHRH-receptor-mediated GH release using the most physiologically native analog
- Research contexts where historical FDA approval and decades of clinical safety data carry weight
- Research populations prioritizing gentle, incremental GH restoration over peak magnitude
A good fit for Ipamorelin
- Research on selective ghrelin-receptor GH release with zero off-target hormonal effects
- Research comparing GH secretagogue selectivity profiles across the class
- Research contexts where the CJC-1295 plus ipamorelin protocol is under study
Consider both across time
Sermorelin and ipamorelin are both clean injectable GH peptides with good safety profiles, but they activate different pituitary receptors. Sermorelin mimics the body's own GHRH signal and has the historical weight of FDA approval (Geref). Ipamorelin activates the ghrelin receptor with the most selective hormonal profile in the class. The two are sometimes combined in clinical protocols for complementary receptor activation, though no controlled study of the combination has been published.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GHRH Receptor
- GHRH Receptor activates Adenylyl Cyclase
- Adenylyl Cyclase connects to cAMP Signaling
- cAMP Signaling connects to GH Transcription
- GH Transcription connects to Growth Hormone Release; Anterior Pituitary connects to Growth Hormone Release
- Growth Hormone Release connects to IGF-1 Elevation
- GHS-R1a Receptor
- GHS-R1a Receptor activates Ghrelin Mimicry
- Ghrelin Mimicry connects to Anterior Pituitary
Sermorelin binds the GHRH receptor on the pituitary (the body's natural 'release growth hormone' signal) and tells it to fire.
Ipamorelin selectively binds the ghrelin receptor on pituitary somatotrophs to trigger growth hormone release without raising cortisol or prolactin.
Research Evidence
Sermorelin has the deepest clinical history: FDA-approved as Geref in 1997 for pediatric growth hormone deficiency diagnostic use, with decades of clinical experience before commercial discontinuation in 2008. The discontinuation was business-driven (manufacturer exit), not safety-driven. Ipamorelin has 48 published studies with human pharmacodynamic data confirming selectivity (Raun 1998, Johansen 1999) and a single Phase II post-surgical GI recovery trial (Beck 2014). Neither has extensive published clinical outcomes data for the body composition and anti-aging endpoints most practitioners prescribe them for.
- 1.
If minimizing off-target hormone effects is the priority, ipamorelin has demonstrated superior selectivity.
- 2.
If clinical track record and regulatory history matter most, sermorelin has decades of human data and prior FDA approval.
- 3.
If combining with CJC-1295 for sustained GH elevation, ipamorelin is the more commonly paired compound in clinical practice.
- 4.
If cost and accessibility are factors, sermorelin is more widely available through compounding pharmacies.
Key Limitations
- •No head-to-head human trial comparing sermorelin and ipamorelin directly.
- •Long-term anti-aging outcome data does not exist for either compound.
- •Individual GH response varies significantly based on age, body composition, and pituitary function.
- •Neither is currently FDA-approved for growth hormone optimization.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Sermorelin
"Sermorelin is the safest way to boost growth hormone naturally"
Plausible but unproven
"It improves sleep quality dramatically"
Plausible but unproven
"It stopped working after a few months"
Plausible but unproven
Ipamorelin
"Ipamorelin is the cleanest GH secretagogue with the fewest side effects"
Plausible but unproven
"Combined with CJC-1295 it mimics natural GH pulsing"
Plausible but unproven
"It helped with my joint pain and recovery"
Anecdotal only
Safety Comparison
Both compounds have favorable safety profiles relative to less selective GH secretagogues. Sermorelin's decades of clinical use established a mild side effect profile (injection site reactions, transient flushing). Ipamorelin's published pharmacodynamic data specifically documents the absence of cortisol, prolactin, and ACTH changes at GH-stimulating doses. Neither compound's long-term safety for off-label anti-aging or body composition use has been characterized in controlled trials.
Sermorelin
Was previously FDA-approved (as Geref) for diagnostic use. Discontinued commercially, not for safety reasons. Common side effects include injection site reactions, flushing, and headache. Generally well-tolerated.
Ipamorelin
Notably selective. Does not elevate cortisol or prolactin at therapeutic doses, a key differentiator from GHRP-2 and GHRP-6. Side effects are generally mild: headache, transient flushing.
What the Research Suggests
Both are effective GH secretagogues with different strengths. Sermorelin has the longer track record. Ipamorelin has the cleaner pharmacological profile.